1. The genome sequence of the sars-associated coronavirus. Science. 2003;300:1399–1404.
2. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–1976.
3. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300:1394–1399.
4. A decade after sars: strategies for controlling emerging coronaviruses. Nat Rev Microbiol. 2013;11:836–848.
5. Sars: clinical virology and pathogenesis. Respirology. 2003;8(Suppl):S6–S8.
6. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105:435–446.
7. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011;186:7264–7268.
8. Antibody-dependent sars coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014;451:208–214.
9. Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge. J Virol. 2012;86:4234–4244.
10. Hospital outbreak of middle east respiratory syndrome coronavirus. N Engl J Med. 2013;369:407–416.
11. Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets. J Infect Dis. 2007;196:1329–1338.
12. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther. 2007;12:1107–1113.
13. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85:12201–12215.
14. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol. 2006;87:641–650.
15. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (Sars-Cov) nucleocapsid protein causes severe pneumonia in mice infected with SARS-Cov. J Immunol. 2008;181:6337–6348.
16. Immunization with Sars Coronavirus vaccines leads to pulmonary immunopathology on challenge with the Sars Virus. PLoS ONE. 2012;7:e35421.
17. Vaccine efficacy in senescent mice challenged with recombinant Sars-Cov bearing epidemic and zoonotic spike variants. PLoS Med. 2006;3:e525.
18. Angiotensin-converting enzyme 2 is a functional receptor for the Sars Coronavirus. Nature. 2003;426:450–454.
19. Cd209l (L-Sign) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci USA. 2004;101:15748–15753.
20. Severe acute respiratory syndrome (Sars)—paradigm of an emerging viral infection. J Clin Virol. 2004;29:13–22.
21. Mucosal immunisation of African Green Monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the Sars Coronavirus spike protein for the prevention of Sars. Lancet. 2004;363:2122–2127.
22. Priming with Sars Cov S DNA and boosting with Sars Cov S epitopes specific for Cd4+ and Cd8+ T cells promote cellular immune responses. Vaccine. 2007;25:6981–6991.
23. A recombinant baculovirus-expressed S Glycoprotein vaccine elicits high titers of Sars-associated coronavirus (Sars-Cov) neutralizing antibodies in mice. Vaccine. 2006;24:3624–3631.
24. Immunopathogenesis of vaccine-enhanced Rsv disease. Vaccine. 2001;20(Suppl. 1):S27–S31.
25. The Sars coronavirus spike glycoprotein is selectively recognized by lung surfactant protein D and activates macrophages. Immunobiology. 2007;212:201–211.
26. Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients. Virus Res. 2009;145:260–269.
27. Severe acute respiratory syndrome (Sars) Coronavirus-induced lung epithelial cytokines exacerbate Sars pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J Virol. 2009;83:3039–3048.
28. Extraordinary Gu-rich single-strand Rna identified from Sars coronavirus contributes an excessive innate immune response. Microbes Infect. 2013;15:88–95.
29. Severe acute respiratory syndrome coronavirus open reading frame (Orf) 3b, Orf 6, and nucleocapsid proteins function as interferon antagonists. J Virol. 2007;81:548–557.
30. Transcriptomic analysis reveals a mechanism for a prefibrotic phenotype in Stat1 knockout mice during severe acute respiratory syndrome coronavirus infection. J Virol. 2010;84:11297–11309.
31. Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection. J Virol. 2012;86:13334–13349.
32. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010;84:9318–9325.
33. Lack of innate interferon responses during Sars coronavirus infection in a vaccination and reinfection Ferret model. PLoS ONE. 2012;7:e45842.
34. Intranasal treatment with poly(I*C) protects aged mice from lethal respiratory virus infections. J Virol. 2012;86:11416–11424.
35. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. J Virol. 2013;87:6551–6559.
36. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog. 2014;10:e1004077.
37. Distinct severe acute respiratory syndrome coronavirus-induced acute lung injury pathways in two different nonhuman primate species. J Virol. 2011;85:4234–4245.
38. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol. 2009;83:7062–7074.
39. Inhibition of Nf-Kappab-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol. 2014;88:913–924.
40. Exacerbated innate host response to Sars-Cov in aged non-human primates. PLoS Pathog. 2010;6:e1000756.
41. Age-related increases in Pgd(2) expression impair respiratory Dc migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J Clin Invest. 2011;121:4921–4930.
42. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82:488–496.
43. Carbohydrate-based immune adjuvants. Expert Rev Vaccines. 2011;10:523–537.
44. Delta inulin: a novel, immunologically active, stable packing structure comprising beta-d-[2 -> 1] poly(fructo-furanosyl) alpha-d-glucose polymers. Glycobiology. 2011;21:595–606.
45. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5n1 vaccine to protect against lethal challenge in ferrets. Vaccine. 2011;29:6242–6251.
46. Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine. 2012;30:5373–5381.
47. Je-Advax vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of Cd8+ T cells and pre-exposure neutralizing antibody. J Virol. 2013;87:4395–4402.
48. An inactivated cell culture Japanese encephalitis vaccine (Je-Advax) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol. 2013;87:10324–10333.
49. A novel hepatitis B vaccine containing a, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine. 2013;31:1999–2007.
50. Randomized clinical trial of immunogenicity and safety of a recombinant H1n1/2009 pandemic influenza vaccine containing advax polysaccharide adjuvant. Vaccine. 2012;30:5407–5416.
51. Immunogenicity and safety of advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled phase 1 study. Vaccine. 2014;32:6469–6477.
52. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol. 2015;89:2995–3007.
53. Effects of toll-like receptor stimulation on eosinophilic infiltration in lungs of Balb/C mice immunized with Uv-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol. 2014;88:8597–8614.
54. Virus-specific memory Cd8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol. 2014;88:11034–11044.
55. Searching for an ideal vaccine candidate among different mers coronavirus receptor-binding fragments—the importance of immunofocusing in subunit vaccine design. Vaccine. 2014;32:6170–6176.